Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults

Luis Perez-de-Llano, Ghislaine Scelo, Trung N. Tran, Tham T. Le, Malin Fagerås, Borja G. Cosio, Matthew Peters, Paul E. Pfeffer, Mona Al-Ahmad, Riyad O. Al-Lehebi, Alan Altraja, Celine Bergeron, Leif H. Bjermer, Anne S. Bjerrum, Lakmini Bulathsinhala, John Busby, Diana J. Cano Rosales, Giorgio W. Canonica, Victoria A. Carter, Jeremy CharriotGeorge C. Christoff, Eve J. Denton, Delbert R. Dorscheid, Maria J. Fernandez Sanchez, João A. Fonseca, Peter G. Gibson, Celine Y. Y. Goh, Liam G. Heaney, Enrico Heffler, Mark Hew, Takashi Iwanaga, Rohit Katial, Mariko S. Koh, Piotr Kuna, Désirée E. S. Larenas-Linnemann, Lauri Lehtimaki, Bassam Mahboub, Neil Martin, Hisako Matsumoto, Andrew N. Menzies-Gow, Nikolaos G. Papadopoulos, Todor A. Popov, Celeste M. Porsbjerg, Pujan Patel, Chin K. Rhee, Mohsen Sadatsafavi, Camille Taille, Carlos A. Torres-Duque, Ming Ju Tsai, Charlotte S. Ulrik, John W. Upham, Anna von Bülow, Eileen Wang, Michael E. Wechsler, David B. Price*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)
1 Downloads (Pure)

Abstract

Rationale: There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. A priori–defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV1 > 80%. Remission was defined using two (exacerbations 1 LTOCS), three (1control or 1lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. Measurements and Main Results: A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three-(1control), three- (1lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73–1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. Conclusions: One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal.

Original languageEnglish
Pages (from-to)869-880
Number of pages12
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume210
Issue number7
DOIs
Publication statusPublished - 1 Oct 2024
Externally publishedYes

Bibliographical note

Copyright 2024 by the American Thoracic Society. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • anti-IgE
  • anti-IL4Ra
  • anti-IL5/5R
  • exacerbation
  • lung function

Cite this